Abbvie Revenue 2024. Last 3 years 0 % / yr. Abbvie had a return on equity of 162.28% and a.
The reported $2.79 earnings per share for the quarter, beating the consensus estimate. Access all of abbvie’s sec filings.
Abbvie Last Announced Its Quarterly Earnings Results On February 2Nd, 2024.
Abbvie said during its investor call that it expected humira to make $9.6 billion in 2024, taking into account u.s.
In 2023, The Collective Market Capitalization Of The Top 20 Pharmaceutical Companies Witnessed A Modest Uptick, Increasing From $3.69 Trillion In 2022 To $3.78.
View a full library of abbvie’s financial new releases.
Abbv) Reported Better Than Expected Revenue For Q4 2023 On Friday, Even As Its Earnings Fell Short Of Forecasts Amid The Ongoing Biosimilar.
Images References :
Affirming Accelerated Growth In 2024.
Abbvie is treading water with sales as humira fades.
In 2023, The Collective Market Capitalization Of The Top 20 Pharmaceutical Companies Witnessed A Modest Uptick, Increasing From $3.69 Trillion In 2022 To $3.78.
The company has raised its dividend payout a tremendous.